Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Aarhus Universitet has 9 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 9 distinct examiners across 8 distinct art units, requiring broad examiner coordination with some shared technical-unit coverage.
LOPEZ, SEVERO ANTON P is the busiest examiner, with 1 pending matter. No examiner dominates the recorded assignments, so counsel should maintain centralized tracking and a consistent biotechnology claim strategy while tailoring each response to its specific art-unit context.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (25%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOPEZ, SEVERO ANTON P | 1 | 34.9% | +40.2% |
| SHEN, YANXIN NMN | 1 | 84.6% | +26.4% |
| PETKOVSEK, DANIEL | 1 | 83.6% | +9.5% |
| CHATTERJEE, JAYANTA | 1 | 44.0% | +70.1% |
| RIGA, MICHAEL ANGELO | 1 | 56.2% | +63.0% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| TRAN, JULIE THI | 1 | 38.2% | +70.9% |
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681619 | AN OPTICAL SYSTEM FOR FREQUENCY CONVERSION OF A SINGLE PHOTON | PETKOVSEK, DANIEL | 30d overdue |
| 18541719 | SYNTHETIC ACTIVATION OF MULTIMERIC TRANSMEMBRANE RECEPTORS | CHATTERJEE, JAYANTA | 26d overdue |
| 18605796 | GENETICALLY ALTERED NFR1 RECEPTOR KINASES | SHEN, YANXIN NMN | — |
| 18009168 | AN AUDIO SYSTEM | TRAN, JULIE THI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18541719 | SYNTHETIC ACTIVATION OF MULTIMERIC TRANSMEMBRANE RECEPTORS | CHATTERJEE, JAYANTA | 26d overdue |
| 18866228 | HIGH-SPEED LASER SPECKLE CONTRAST IMAGING | LOPEZ, SEVERO ANTON P | — |
| 18605796 | GENETICALLY ALTERED NFR1 RECEPTOR KINASES | SHEN, YANXIN NMN | — |
| 18570210 | SORLA MINI-RECEPTOR FOR TREATMENT OF ALZHEIMER'S DISEASE | RIGA, MICHAEL ANGELO | — |
| 18040084 | NOVEL PEPTIDES AND USES THEREOF | WANG, CHANG YU | — |
| 18009168 | AN AUDIO SYSTEM | TRAN, JULIE THI | — |
| 17276432 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCERS RESISTANT TO IMMUNE CHECKPOINT THERAPY | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 3791 | 2 |
| 1663 | 1 |
| 2874 | 1 |
| 1662 | 1 |
| 1634 | 1 |
| 1675 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866228 | HIGH-SPEED LASER SPECKLE CONTRAST IMAGING | LOPEZ, SEVERO ANTON P | 3791 | §103 | Non-Final OA | — | Pending | Nov 15, 2024 |
| 18605796 | GENETICALLY ALTERED NFR1 RECEPTOR KINASES | SHEN, YANXIN NMN | 1663 | §102§103§112 | Final Rejection | — | Pending | Mar 14, 2024 |
| 18681619 | AN OPTICAL SYSTEM FOR FREQUENCY CONVERSION OF A SINGLE PHOTON | PETKOVSEK, DANIEL | 2874 | §103§112 | Non-Final OA | 30d overdue | Pending | Feb 06, 2024 |
| 18541719 | SYNTHETIC ACTIVATION OF MULTIMERIC TRANSMEMBRANE RECEPTORS | CHATTERJEE, JAYANTA | 1662 | §102§103§112 | Final Rejection | 26d overdue | Pending | Dec 15, 2023 |
| 18570210 | SORLA MINI-RECEPTOR FOR TREATMENT OF ALZHEIMER'S DISEASE | RIGA, MICHAEL ANGELO | 1634 | §112 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18040084 | NOVEL PEPTIDES AND USES THEREOF | WANG, CHANG YU | 1675 | §112DP | Non-Final OA | — | Pending | Jan 31, 2023 |
| 18009168 | AN AUDIO SYSTEM | TRAN, JULIE THI | 3791 | §103§112 | Non-Final OA | — | Pending | Dec 08, 2022 |
| 17276432 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCERS RESISTANT TO IMMUNE CHECKPOINT THERAPY | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | — | Pending | Mar 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAarhus Universitet has 8 pending office actions as of October 2026, spread across 7 art units and 8 examiners.
Severo Anton P Lopez has the most, with 1 of Aarhus Universitet's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
